Month: April 2024

WithSecure Corporation, Stock Exchange Release, 8 April 2024, 8:15 EEST President and CEO of WithSecure steps down; Chief Product Officer Antti Koskela appointed as interim CEO Juhani Hintikka, President and CEO of WithSecure, has today announced that he steps down from his position in the company. The decision to step down follows the Supreme Court ruling of 5 April 2024 where Juhani Hintikka was found guilty of abuse of inside information related to a matter dating back to 2014, years before Hintikka joined WithSecure. “This decision does not relate to Juhani Hintikka’s tenure at WithSecure at all. Juhani Hintikka has professionally navigated WithSecure through a significant transformation and transition into becoming a leading European cyber security company and I want to warmly thank him for that. Due to the Supreme Court ruling Hintikka...

Oslo, 8 April 2024 – DNO ASA, the Norwegian oil and gas operator, today announced that a final investment decision has been made for the development of the Brasse field, to be renamed Bestla, based on a tie-back to the nearby production facilities of the Brage field. Bestla is Brage’s grandmother in Norse mythology. By long-standing practice, all Norwegian oil and gas fields carry Norse, Nordic or Norwegian names. Bestla (PL740), located in the northern North Sea, is estimated to contain 24 million barrels of oil equivalent (MMboe) in recoverable reserves and is expected to come on stream as early as the first half of 2027, subject to government approval of a plan for development and operation (PDO) to be submitted later this month. In addition to DNO Norge AS (39.3 percent), the Bestla partnership includes OKEA ASA (39.3 percent) as operator,...

Grieg Seafoods harvest volume for the first quarter of 2024 was approximately 21 000 tonnes GWT. Harvest volume (tonnes GWT) by region for the quarter:Rogaland: 9 400Finnmark: 5 700British Columbia: 700Newfoundland: 5 200 The complete Q1 2024 report will be released on Thursday 16 May 2024 at 06:00 CEST. For enquiries, please contact:Andreas Kvame, CEOCell phone: +47 907 71 441 Atle Harald Sandtorv, CFOCell phone +47 908 45 252About Grieg SeafoodGrieg Seafood ASA is one of the world’s leading salmon farmers. Our farms are in Rogaland and Finnmark in Norway, as well as in British Columbia and Newfoundland in Canada. Our headquarter is in Bergen, Norway. Grieg Seafood ASA was listed at the Oslo Stock Exchange in June 2007. Sustainable farming practices are the foundation of Grieg Seafood’s operations. The lowest possible environmental...

Generative AI chatbot integrated with Enterprise Data Lake generates high-quality, actionable answers to complex business queries SINGAPORE, April 07, 2024 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), the leading end-to-end, hybrid multicloud solutions company, today announced that GLP is working with Foundry for AI by Rackspace (FAIR™) and Microsoft to enable Global Logistic Properties Limited (GLP), a leading global business builder, owner, developer and operator of logistics real estate, data centres, renewable energy, to become more data-driven in their asset management strategies. A Generative AI-enabled intelligent system was developed by integrating Microsoft Azure OpenAI Service. The system is capable of deep diving into its data to answer complex business inquiries. GLP, an early adopter of cutting-edge...

perth, April 08, 2024 (GLOBE NEWSWIRE) — PERSEUS OFFER UNCONDITIONAL AND BEST AND FINAL Perth, Western Australia/ April 8, 2024/Perseus Mining Limited (ASX/TSX: PRU) (Perseus or PRU) refers to its off-market takeover bid under Chapter 6 of the Australian Corporations Act for all the current and to be issued ordinary shares in OreCorp Limited (ASX: ORR) (OreCorp or ORR) (Offer).1 As at April 5, 2024, Perseus has a relevant interest in 239,542,398 OreCorp Shares representing 51.03% of OreCorp Shares on issue. As such, Perseus has declared that the Offer is now:unconditional; and best and final in the absence of a competing proposal.OreCorp Shareholders should Accept the Offer now in respect of Your OreCorp Shares. Proposed OreCorp Board Changes Perseus refers to OreCorp’s announcement today noting that OreCorp is actively working...

perth, April 08, 2024 (GLOBE NEWSWIRE) — CHANGE TO PERSEUS’S SENIOR MANAGEMENT TEAM Perth, Western Australia/April 8, 2024/Perseus Mining Limited (ASX/TSX: PRU) wishes to advise that its Chief Operating Officer (COO), Mr. David Schummer, has advised that he will resign from the Company with effect from September 30, 2024, to pursue new employment opportunities located closer to his family in North America.  Mr. Schummer has agreed to remain in his role with Perseus until the end of September to manage a number of strategic work streams that are currently underway at the mine sites and to assist with the smooth transition to his successor.  The process to select and appoint a new COO will commence immediately with consideration being given to both internal and external candidates for the role. Perseus’s Chairman and CEO Jeff Quartermaine...

Real-world data demonstrate non-classical mutations are present in 20-30% of all patients with EGFRm NSCLC Emerging data show non-classical EGFR mutations can be co-expressed with the classical L858R mutation, a setting characterized by shorter duration of response to osimertinib BDTX-1535 profile differentiated as the most advanced fourth-generation oral TKI in clinical development addressing the full spectrum of classical, non-classical, and C797S resistance EGFR mutations CAMBRIDGE, Mass., April 07, 2024 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, presented real-world evidence of the evolving epidermal growth factor receptor (EGFR) mutation landscape in non-small cell...

RP1 monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent and complete response rate of nearly 22 percent in evaluable patients SAN DIEGO, April 07, 2024 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the presentation of interim results from ARTACUS, a Phase 1/2 clinical trial evaluating RP1 monotherapy for the treatment of skin cancers in patients who have had solid organ or hematopoietic cell transplants, by Michael R. Midgen, M.D., of the University of Texas MD Anderson Cancer Center during an oral session at the AACR 2024 Annual Meeting in San Diego. The results were initially presented late last year at the 38th Annual Meeting of the Society...

WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) — iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced a poster presentation of preclinical data on EOS-984, a potential first-in-class small molecule inhibitor targeting the equilibrative nucleoside transporter 1 (ENT1) in oncology, at the American Association for Cancer Research (AACR) Annual Meeting, being held April 5-10, 2024 in San Diego, California. Based on the Company’s discovery and characterization of ENT1 in adenosine-mediated immunosuppression, this novel mechanism allows for the intracellular accumulation of adenosine, which then suppresses proliferation and effector function of T cells in the...

Regulatory applications for linvoseltamab currently under review by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) TARRYTOWN, N.Y., April 07, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the oral plenary session presentation of positive pivotal data from the Phase 1/2 LINKER-MM1 trial of linvoseltamab in patients with relapsed/refractory (R/R) multiple myeloma (MM) at the American Association for Cancer Research (AACR) Annual Meeting 2024 in San Diego. Linvoseltamab is an investigational bispecific antibody designed to bridge B-cell maturation antigen (BCMA) on multiple myeloma cells with CD3-expressing T cells to facilitate T-cell activation and cancer-cell killing. “The presentation of these pivotal results in an oral plenary session at AACR recognizes...